Smart Patients Get Smart Care™

The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients

Test Before Treat™ One-pager

In science and medicine, information is constantly changing and may become out-of-date as new data emerge. All articles and interviews are informational only, should never be considered medical advice, and should never be acted on without review with your health care team.

The PDF document below is a one-page summary of what you need to know about the three most important tests that need to be performed to guide your CLL or SLL treatment selection.

Please read it and print it out to share with your healthcare provider, if need be, or with other patients who might also benefit from this information.


As new and better treatments are developed to treat Chronic Lymphocytic Leukemia, and Small Lymphocytic Lymphoma (CLL / SLL), testing for subtypes of the disease is becoming more important for prognosis and selection of the best treatment options.
Patient, Know Thyself Mark Hoffman is a long-time CLL patient advocate and facilitator of the CLL Society Patient & Caregiver Support Group in San Diego, CA. In this article from Cancer Health, Mark echoes the importance of the Test Before Treat™ campaign by sharing his story. When Mark was
At the American Society of Hematology’s (ASH) 2020 conference, there was research on looking at the genome of CLL and how different genetic markers might have predictive and value. Dr. Brian Koffman, Chief Medical Officer and Executive Vice President of CLL Society, interviewed Dr. Adrian Wiestner, a senior investigator at
CLL Society On Demand Ed Forum: ASH 2020 Comes to You – Session 1: Encouraging Updates on Drugs in Development + the Sad State of Test Before Treat Recorded Thursday, February 4, 2021 Continue to Session 2: CLL Treatments: Chemotherapy, Immunotherapy, and Targeted Agents CLL Society Resources Download